Pilot Trial To Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Girentuximab I-124 (Primary) ; Pazopanib; Sunitinib
- Indications Renal cell carcinoma
- Focus Diagnostic use
- 27 Dec 2016 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
- 27 Dec 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
- 28 Mar 2016 Planned End Date changed from 1 Apr 2016 to 1 Apr 2017, according to ClinicalTrials.gov record.